Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Christophe Le Tourneau, Martin Schüler et al.|The Lancet Oncology|2023Cited by 195
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trialKarim Fizazi, Mika Mustonen, Christophe Massard et al.|The Lancet Oncology|2014Cited by 194
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?Christophe Massard, Karim Fizazi|British Journal of Cancer|2007Cited by 46
Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castrationresistant prostate cancer: a report from the PETRUS prospective studyChristophe Massard, Françoise Farace|Oncotarget|2016Cited by 36
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical TrialsJia Liu, Anthony M. Joshua, Lesley Seymour et al.|Journal of Clinical Oncology|2025Cited by 11